期刊文献+

培美曲塞联合顺铂治疗晚期乳腺癌的疗效观察 被引量:14

下载PDF
导出
摘要 在我国城市女性中,乳腺癌的发病率居第一、二位,是女性癌症死亡的最常见原因之一。随着蒽环类和紫杉类等新药上市,晚期乳腺癌的疗效有较大提高,合理治疗可使患者得到长期生存,但是长程的化疗容易使患者出现多药耐药,其中有50%的患者易出现复发转移,而目前临床上尚缺乏公认有效的解救方案。因此,如何治疗药物化疗失败的晚期乳腺癌已成为临床的一大难题。我院使用培美曲塞联合顺铂治疗经多周期蒽环类和紫杉类等化疗失败后出现复发转移的晚期乳腺癌患者24例,取得了满意的效果,现报告如下。
出处 《中国癌症杂志》 CAS CSCD 北大核心 2011年第2期159-160,共2页 China Oncology
  • 相关文献

参考文献8

  • 1徐兵河.改变乳腺癌临床实践的重要临床试验的回顾与评述[J].中国癌症杂志,2005,15(5):408-412. 被引量:22
  • 2王中吉.乳腺癌预后指标的临床意义[J].肿瘤学杂志,2002,8(4):233-235. 被引量:13
  • 3Olschewski M, Schulgen G, Schumaeher M, et al. Quality of life assessment in clinical cancer research [ J ] . Br J Cancer, 1994, 70(1): 1-5.
  • 4张玺炜,高洪元,储冬英,赵子仪.培美曲塞联合顺铂方案治疗蒽环类及紫杉类治疗失败的晚期转移性乳腺癌的初步研究[J].中国癌症杂志,2009,19(9):697-700. 被引量:20
  • 5Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate [ J ]. Clin Ther, 2005, 27(9): 1343-1382.
  • 6Martin M, Blasinska-Morawiec M, Salas JF, et al. A multicenter, single-arm phase Ⅱ study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer [ J ] . Clin Breast Cancer, 2009, 9(3): 155-160.
  • 7Llombart-Cussac A, Martin M, Harbeck N, et al. A randomized, double-blind, phase Ⅱ study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer [ J ]. Clin Cancer Res, 200?, 13(12): 3652-3659.
  • 8Dent SF, Gertler S, Verma S, et al. A phase Ⅱ study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer [ J ] . Cancer Chemother Pharmacol, 2010, 65(3): 557-561.

二级参考文献35

  • 1沈镇宙.乳腺癌的预后指标.肿瘤学新理论与新技术(第1版)[M].上海:上海科技教育出版社,1997.723.
  • 2Boyle P,Ferlay J.Cancer incidence and mortality in Europe,2004[J].Annal Oncol,2005,16(3):481-488.
  • 3Kataja V,Castiglione M,on behalf of the ESMO Guidelines Working Group.Locally recurrent or metastatic breast cancer.ESMO clinical recommendations for diagnosis,treatment and follow-up[J].Annal Oncol,2008,19(2):9-11.
  • 4Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].Cancer J Clin,2005,55(2):74-108.
  • 5Spielmann M,Marlin M,Namer M,et al.Activity of pemetrexed (ALIMTA,multitargeted antifolate,LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane:an interim analysis[J].Clin Breast Cancer,2001,2(1):47-51.
  • 6Hanauske AR,Chen V,Paoletti P,et al.Pemetrexed disodium:a novel antifolate clinically active against multiple solid tumors[J].Oncologist,2001,6(4):363-373.
  • 7Vogelzang N J,Ruathoven JJ,Symanowski J,et al.Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[J].J Clin Oncol,2003,21(14):2636-2644.
  • 8Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with nonsmall cell lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1589-1597.
  • 9Scagliotti GV,Parikh P,yon Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551.
  • 10Paridaens R,Dirix L,Dumez H,et al.Phase Ⅰ/Ⅱ pharmacokinetic study of pemetrexed and epirubiein in patients with locally advanced or metastatic breast cancer[J].Clin Breast Cancer,2007,7(11):861-866.

共引文献49

同被引文献137

引证文献14

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部